Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sebi slaps Rs 8 lakh...

    Sebi slaps Rs 8 lakh fine on Aanjaneya Lifecares officials

    Written by supriya kashyap kashyap Published On 2017-04-20T09:06:08+05:30  |  Updated On 20 April 2017 9:06 AM IST
    Sebi slaps Rs 8 lakh fine on Aanjaneya Lifecares officials

    New Delhi : Markets watchdog Sebi imposed a total penalty of Rs 8 lakh on Aanjaneya Lifecares five senior officials for not complying with model code of conduct under prevention of insider trading regulation.


    It has slapped a fine of Rs 5 lakh on Kannan Vishwanath, Vice Chairman and Managing Director of Aanjaneya Lifecare (now known as Dr Datsons Labs Ltd) for trading in the company's shares without obtaining pre-clearance from the firm as required, Sebi said in an order.


    Besides, he executed "opposite transactions within 6 months of the earlier transaction". By indulging in such activities, he violated model code of conduct for prevention of insider trading, it added.


    Further, a penalty of Rs 3 lakh has been imposed on board of directors Vishwanath, Shashikant Babanrao Shinde, Prabhat Kumar Goyal, Paul Chakkapah Naythatil and compliance officer Yogesh Patel for failing to implement the code of conduct and monitor the trades for prevention of insider trading, as per the order.


    "For orderly conduct of securities market, it is of utmost importance that the key managerial personnel including the board of directors and compliance officer shall adhere to the statutory code on insider trading," Sebi said.


    Under the norms, all directors and officers of the firm who intend to deal in the securities of a company are required to pre-clear the transaction.


    Further, such officials cannot enter into an opposite transaction sell or buy any number of shares during the next six months following the prior transaction.

    Aanjaneya LifecareDr Datsons LabsKannan VishwanathPaul Chakkapah NaythatilPrabhat Kumar GoyalShashikant Babanrao Shinde
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok